Today that its lead drug candidate announced.

Similar trends in individual responses have been observed to-date in the on-going Stage 1/2 recurrent glioblastoma clinical trial with approximately 65 percent of sufferers experiencing disease control. It really is highly encouraging to discover that ANG1005 shows the potential to be effective in metastatic mind cancers and against drug resistant tumors, that are aggressive and also have few treatment plans highly, commented Jan Drappatz, MD, Center for Neuro-Oncology at Dana-Farber Cancer Institute, Section of Neurology at Brigham and Women’s Medical center, and, Harvard Medical School, and business lead investigator for Boston-area study centers.Boehringer Ingelheim completes individual enrolment for interferon-free of charge hepatitis C treatment Boehringer Ingelheim today announced the completion of individual enrolment for a Stage IIa clinical trial investigating a fresh interferon-free, all-oral, direct-performing antiviral mixture treatment for individuals with genotype-1a chronic hepatitis C virus disease. The trial is executed in collaboration with Presidio Pharmaceuticals, Inc. The principal endpoint of the trial is certainly sustained virologic response 12 weeks after treatment is normally completed . Both ongoing companies will retain all legal rights with their respective compounds.